Q3 revenue is expected at $22.7 million, matching a year ago, while tissue-based test volume fell 11%.
MDxHealth SA (MDXH) reported preliminary Q3 2026 revenue of $22.7 million, matching the prior year, but below expectations. The company cited sales force turnover and discontinued product as reasons. CEO Michael K. McGarrity expects a return to growth and will provide more details on November 12.
How this was made
The 30-second read
Why it matters
The company suspended full-year 2026 revenue guidance, citing disrupted sales execution and a tissue-based test volume decline, and plans to provide corrective-action detail with the full Q3 results on Nov. 12.
Market read
Traders should reassess MDXH’s 2026 revenue risk given the guidance suspension and quantified volume decline, and monitor for stabilization signals ahead of the Nov. 12 earnings call.
What to watch
Preliminary unaudited figures and the lack of full guidance detail mean the market may overreact until the company reports corrective actions, territory fortification progress, and any changes to reimbursement or collection assumptions.
Background
mdxhealth reported preliminary unaudited Q3 2026 revenue from continuing operations and attributed underperformance to unexpected sales-force turnover after discontinuing Resolve mdx.
Ticker impact
mdxhealth suspends full-year 2026 revenue guidance after preliminary Q3 revenue fell short and tissue-based test volume dropped 11%.
Likely near-term pressure as investors reprice 2026 revenue risk and wait for updated corrective-action details.
The article is a company-specific preliminary results update with an explicit guidance suspension and quantified volume decline, both directly affecting MDXH’s forward outlook.
Market effects
Highlights execution and commercial-force sensitivity in precision diagnostics, potentially affecting sentiment toward urology diagnostics peers.
Limited direct regional spillover; primarily a US-listed small-cap biotech/diagnostics sentiment read-through.
Low global macro relevance; mostly company-specific execution and guidance risk.
Counterpoint
Management frames the issue as sales-force turnover after Resolve mdx discontinuation, not a demand collapse, implying guidance could be reinstated if execution normalizes.
Key entities
- companyMDxHealth SA
NASDAQ-listed urology-focused precision diagnostics company issuing preliminary Q3 results and suspending full-year 2026 revenue guidance.
- personMichael K. McGarrity
CEO of mdxhealth, commenting that sales-force turnover disrupted forecast accuracy after Resolve mdx discontinuation.
